- Price is above Fair Value, showing premium demand versus the model.
- Next-week expectancy is positive at 55.68% based on similar historical setup states.
CRVS
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Corvus Pharmaceuticals Inc · Healthcare · Biotechnology
Latest close
13.26 USD
1.5%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -10.5% below the Trend Line and sits at 40.2% of its 52-week range. The latest completed week returned 1.5%, after a -12.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 50/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.
Setup score
39
out of 100
Latest Close
13.26 USD
31 Jul 2026
1W Return
1.5%
latest completed week
4W Return
-12.9%
short-term follow-through
12W Return
-14.7%
quarterly tape
Trend Breadth
76.9%
40 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.5%
Latest completed week; four-week move -12.9%.
Indicator stack
42/49
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 55.68%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
50/100 conviction; expected move 16.0%.
News sentiment
54/100
59 relevant articles in the latest sentiment read.
Event risk
4d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -10.5% below the Trend Line and sits at 40.2% of its 52-week range. The latest completed week returned 1.5%, after a -12.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3412-week average 0.45
12-week confirmation
Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.34Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -12.9% over four weeks, -14.7% over 12 weeks, and 223.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year40
Trend breadth76.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.32Latest activity-pressure read.
Pressure change54.3%Four-week change in activity pressure.
Leadership5.84Latest relative-leadership reading.
RS change-75.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 67%
Model confidence 64%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength66/100Blend of value, momentum, and quality. Underlying universe rank 35; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -15.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -17.2% Net share repurchases relative to market value.
- Shareholder yield
- -17.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
CRVS shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.21, expected move of 16.0%, and Sharemaestro trend signal inactive.
Conviction50/100
Expected move16.0%
Put/call volume0.21
Insider activity9 / 0
9 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment54/100
Weighted news tone is neutral across 59 relevant articles.
15 positive · 39 neutral · 5 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move16.0%Nearest-chain priced movement where available.
52-week drawdown-50.8%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher12 of 2614 weeks finished lower.
Best week+13.3%Week of 26 Jun.
Worst week-20.8%Week of 15 May.
Latest week+1.5%Week of 31 Jul.
Shape of recent returns
Strong gains7
Modest gains5
Flat weeks0
Modest losses6
Sharp losses8
Recent vol9.3%13-week weekly-return volatility.
Base vol30.6%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew15.4% / -7.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape45/100
Trend, activity pressure, participation, and risk combine to a 45/100 tape read.
Indicator analysis33/100Latest 12-week confirmation: trend 2/12, activity pressure 0/12, relative leadership 9/12.
Activity pressure 0.34; No reversal markers Next-Week ExpectancyPositive 55.68%Next-week expectancy is positive with a 55.68% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 90; Small Cap Core rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100CRVS shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.21, expected move of 16.0%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 16.0% Sentiment54/100Weighted news tone is neutral across 59 relevant articles.
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 Insiders9 / 09 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 13.26 USD | 1.5% | 14.82 USD | 6.18 USD | -0.32 | 5.84 | 4.1M | Off |
| 24 Jul 2026 | 13.07 USD | -12.3% | 14.62 USD | 6.11 USD | -0.21 | 6.22 | 3.8M | Off |
| 17 Jul 2026 | 14.90 USD | -4.9% | 14.44 USD | 6.04 USD | -0.14 | 20.55 | 5.8M | Off |
| 10 Jul 2026 | 15.67 USD | 2.9% | 14.20 USD | 5.96 USD | -0.40 | 23.35 | 7.3M | Off |
| 3 Jul 2026 | 15.23 USD | 12.9% | 13.95 USD | 5.88 USD | -0.71 | 23.97 | 6.4M | Off |
| 26 Jun 2026 | 13.49 USD | 13.3% | 13.74 USD | 5.80 USD | -1.02 | 12.54 | 8.1M | Off |
| 19 Jun 2026 | 11.91 USD | -0.2% | 13.59 USD | 5.73 USD | -1.16 | -3.80 | 5.0M | Off |
| 12 Jun 2026 | 11.93 USD | 7.3% | 13.48 USD | 5.66 USD | -1.05 | -0.08 | 6.2M | Off |
| 5 Jun 2026 | 11.12 USD | -10.4% | 13.38 USD | 5.60 USD | -0.96 | -3.76 | 7.1M | Off |
| 29 May 2026 | 12.41 USD | -1.6% | 13.26 USD | 5.55 USD | -0.82 | 3.58 | 7.2M | Off |
| 22 May 2026 | 12.61 USD | 2.4% | 13.11 USD | 5.50 USD | -0.81 | 9.53 | 12.0M | On |
| 15 May 2026 | 12.31 USD | -20.8% | 12.94 USD | 5.43 USD | -0.72 | 9.63 | 10.9M | On |
| 8 May 2026 | 15.55 USD | 0.6% | 12.76 USD | 5.37 USD | -0.59 | 39.81 | 5.9M | On |
| 1 May 2026 | 15.46 USD | -3.9% | 12.48 USD | 5.29 USD | -0.49 | 48.98 | 5.9M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.